Bavarian Nordic A/S (Bavarian Nordic A/S) Debt-to-Asset

: 0.01 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Bavarian Nordic A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7 Mil. Bavarian Nordic A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14 Mil. Bavarian Nordic A/S's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $2,100 Mil. Bavarian Nordic A/S's debt to asset for the quarter that ended in Dec. 2023 was 0.01.

Bavarian Nordic A/S Debt-to-Asset Historical Data

The historical data trend for Bavarian Nordic A/S's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.26

0.05

0.09

0.14

0.01

Bavarian Nordic A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.14	0.06	0.06	0.01	0.01

Competitive Comparison

For the Biotechnology subindustry, Bavarian Nordic A/S's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bavarian Nordic A/S Debt-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Bavarian Nordic A/S's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic A/S's Debt-to-Asset falls into.

Bavarian Nordic A/S Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bavarian Nordic A/S's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.81	+	14.449)	/	2100.019
	=	0.01

Bavarian Nordic A/S's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.81	+	14.449)	/	2100.019
	=	0.01

Bavarian Nordic A/S (OTCPK:BVNRY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bavarian Nordic A/S Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BVNKF:USA BAVAc:UK 0DPB:UK BAVA:Denmark BV3:Germany

Address

Philip Heymans Alle 3, Hellerup, DNK, DK-2900

Website

https://www.bavarian-nordic.com

Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.